Abstract:BackgroundThe pharmacokinetic properties of the immediate-release (IR) and the recently developed controlled-release (CR) formulation of pregabalin are dose proportional. Pregabalin IR can be taken with or without food.ObjectivesThis analysis characterizes the effect of food on pregabalin CR. The objectives of this analysis were: (1) to evaluate the effect of administration time and fat or caloric content of an accompanying meal on the pharmacokinetic properties of a single dose of pregabalin CR (330 mg) relative to a single dose of pregabalin IR (300 mg); (2) to evaluate the pharmacokinetic properties of a single dose of pregabalin CR administered fasted relative to a single dose of pregabalin CR administered immediately after food; and (3) to determine the safety and tolerability of single-dose administration of pregabalin CR and IR with and without food.MethodsThe effect of food on the pharmacokinetic properties of pregabalin CR was determined in five phase I, open-label, single-dose, crossover studies (24–28 participants/study). Caloric and fat content of meals were varied and treatments were administered in the morning, at midday, or in the evening. Blood samples were collected up to 48 h post-dose. Pharmacokinetic parameters were estimated from plasma concentration–time data using standard noncompartmental methods. Adverse events were monitored throughout all studies.ResultsOne hundred and twenty-eight healthy participants (19–54 years of age) received pregabalin. Peak plasma concentrations (Cmax) were lower for CR than the respective pregabalin IR doses, and time to Cmax occurred later. When pregabalin CR was administered with food at midday or in the evening, total exposures [area under the plasma concentration–time curve from time zero extrapolated to infinite time (AUC∞)] were equivalent for pregabalin CR and IR formulations regardless of fat or caloric content. When pregabalin CR was administered with an 800–1,000 calorie medium-fat breakfast, AUC∞ was equivalent for pregabalin CR and IR. Bioequivalence criteria for comparison of pregabalin CR after a low- or medium-calorie breakfast relative to pregabalin IR were not met; however, bioavailability of the pregabalin CR vs. IR formulation was relatively high (75–86 %). When pregabalin CR was administered fasted, the AUC∞ was 70–78 % of the AUC∞ of pregabalin CR administered with food and bioequivalence criteria were not met. Additionally, the AUC∞ of the pregabalin CR formulation administered fasted was 62–69 % of that of pregabalin IR administered fasted and bioequivalence criteria were not met. Single-dose pregabalin CR and IR were well tolerated in all studies, with no serious or severe adverse events reported.ConclusionTime of day of administration and the fat and caloric content of the accompanying meal had minimal overall effect on the pharmacokinetic properties and bioavailability of the pregabalin CR formulation.

Pharmacokinetics of Pregabalin Controlled-Release in Healthy Volunteers: Effect of Food in Five Single-Dose, Randomized, Clinical Pharmacology Studies

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Pregabalin for Postherpetic Neuralgia in A Population of Chinese Patients

Is It Appropriate Regarding Patient Preference to Take Myrtol Standardized Enteric-Coated Soft Capsules after a Meal Rather Than at Fasted State? A Food–drug Pharmacokinetic Interaction Study in Healthy Chinese Volunteers

Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects

Randomised clinical trial: the effects of pregabalin vs placebo on functional dyspepsia

Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation

Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy

Effects of Food on Absorption of Ozagrel after Oral Administration in Healthy Volunteers

Effect of a High‐Fat Meal on the Pharmacokinetics of an Immediate Release Atogepant Tablet

Effect of Food on Pharmacokinetics and Pharmacodynamics of Fenofibric Acid aftera Single Oral Dose of Fenofibrate Sustained-Release Capsule

The Effects of Food on the Bioavailability of Fenofibrate Administered Orally in Healthy Volunteers via Sustained-Release Capsule

Dose–response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia

Design and optimization of gastro-floating sustained-release tablet of pregabalin: In vitro and in vivo evaluation

Efficacy of Pregabalin in the Treatment of Postherpetic Neuralgia : a Meta-Analysis of Randomized Controlled Trials

A Comparative Bioavailability Study of Carbamazepine Tablets and a Chewable Tablet Formulation

Effect of Baseline Characteristics on the Pain Response to Pregabalin in Fibromyalgia Patients with Comorbid Depression

Effects of oral pregabalin on postoperative sleep of patients after video-assisted thoracoscopic surgery: a randomized double-blind controlled trial

A phase 4 randomized active-controlled clinical study to compare the efficacy and safety of sustained-release pregabalin with immediate-release pregabalin in type 2 diabetic patients with peripheral neuropathic pain

The Effect of Food on Tramadol and Celecoxib Bioavailability Following Oral Administration of Co-Crystal of Tramadol–Celecoxib (CTC): A Randomised, Open-Label, Single-Dose, Crossover Study in Healthy Volunteers

Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas

Effect of Food on the Pharmacokinetics of Quizartinib